NoBlood

Revised labeling for epoetin alfa (Procrit, Ortho Biotech) was issued advising dosing interruption and modification with patients in whom the rate of rise of hemoglobin exceeds 1 g/dL over a 2-week period.

Formulary

Revised labeling for epoetin alfa (Procrit, Ortho Biotech) was issued advising dosing interruption and modification with patients in whom the rate of rise of hemoglobin exceeds 1 g/dL over a 2-week period. The new labeling also recommends that the target hemoglobin in patients with cancer should not exceed 12 g/dL in men and women. Epoetin alfa therapy should be withheld if hemoglobin levels are 13 g/dL or above.